(Q66082751)

English

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC)

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (English)

0 references

sponsor

Hoffmann-La Roche

0 references

start time

13 September 2016

0 references

end time

27 June 2018

0 references

number of participants

243